MS-553

Phase 1Small molecule

SShenzhen MingSight Relin Pharmaceuticals Co., Ltd.

MS-553 is one of 71 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Diabetic RetinopathyActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Diabetic RetinopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

PEG-Intron

Merck & Co.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Diabetic Retinopathy

NCT04187443

Clinical

Trials by Indication[1]

Diabetic Retinopathy1 trial

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Recruiting·SShenzhen MingSight Relin Pharmaceuticals Co., Ltd.·Phase 1·NCT04187443·45 enrolled

Elective1 trial

A Study Of The Selective PKC-β Inhibitor MS- 553

Terminated·MMingSight Pharmaceuticals, Inc·Phase 1/2·NCT03492125·60 enrolled

Efficacy and Safety1 trial

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Terminated·SShenzhen MingSight Relin Pharmaceuticals Co., Ltd.·Phase 1/2·NCT05272813·13 enrolled

Lymphoma1 trial

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Terminated·MMingSight Pharmaceuticals, Inc·Phase 1/2·NCT05720052·8 enrolled

Unspecified1 trial

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

Completed·MMingSight Pharmaceuticals Pty Limited·Phase 1·NCT02406989·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MS-553. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MS-553 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MS-553. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShenzhen MingSight Relin Pharmaceuticals Co., Ltd.

MS-553

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Diabetic Retinopathy1 trial

Elective1 trial

Efficacy and Safety1 trial

Lymphoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News